Abstract Rett syndrome (RTT), an X-linked dominant neurodevelopmental disorder in females, is caused mainly by de novo mutations in the methylCpG-binding protein 2 gene (MECP2). Here we report mutation analysis of the MECP2 gene in 87 patients with RTT from the Czech and Slovak Republics, and Ukraine. The patients, all girls, with classical RTT were investigated for mutations using bi-directional DNA sequencing and conformation sensitive gel electrophoresis analysis of the coding sequence and exon/intron boundaries of the MECP2 gene. Restriction fragment length polymorphism analysis was performed to confirm the mutations that cause the creation or abolition of the restriction site. Mutationnegative cases were subsequently examined by multiple ligation-dependent probe amplification (MLPA) to identify large deletions. Mutation screening revealed 31 different mutations in 68 patients and 12 nonpathogenic polymorphisms. Six mutations have not been previously published: two point mutations (323T>A, 904C>T), three deletions (189_190delGA, 816_832del17, 1069delAGC) and one deletion/inversion (1063_1236del174;1189_1231inv43). MLPA analysis revealed large deletions in two patients. The detection rate was 78.16%. Our results confirm the high frequency of MECP2 mutations in females with RTT and provide data concerning the mutation heterogeneity in the Slavic population.
Introduction
Rett syndrome (RTT; OMIM 312750), first described by the Austrian pediatrician Rett (1966) , is one of the leading causes of mental retardation and developmental regression in girls. Its prevalence is estimated to be from 1:10,000 to 1:15,000 females worldwide with most cases being sporadic (Hagberg 1995) . Patients with classical RTT show an apparently normal psychomotor development during the first 6-18 months of life. Thereafter, they enter a short period of developmental stagnation followed by a rapid regression in language and motor development. Purposeful hand use is often lost and replaced by repetitive, stereotypic movements. Additional symptoms include acquired microcephaly, gait ataxia/apraxia, seizures, and episodic apnea and/or hyperpnea (Hagberg et al. 1983; Naidu 1997) . The causative gene was mapped to Xq28 and identified as the MECP2 gene . It encodes the methyl-CpG-binding protein 2 (MeCP2; OMIM 300005), which is involved in regulation oftranscription repression, epigenetic gene silencing ; Van den Veyver and Zoghbi 2000) , and RNA splicing (Young et al. 2004) . Several different MECP2 mutations have been identified in up to 90% of classical RTT patients worldwide. The mutation rate in atypical cases is much lower: 20-40% (Hoffbuhr et al. 2002; Laccone et al. 2004; Amir et al. 2005 ). We present a mutation analysis of the MECP2 gene in RTT patients from the Czech Republic, Slovakia, and Ukraine. We tested 87 patients with classical RTT to ascertain the spectrum of disease-causing mutations of MECP2 gene in the Slavic population.
Subjects and methods

Patients
Most of 87 unrelated sporadic female patients with a clinical diagnosis of RTT were diagnosed in neurological, genetic, or pediatric departments. Several patients were identified from Institutes of social work for mentally retarded children. All patients included in this study were diagnosed as having classical RTT, with psychomotor regression after a period of normal development, severe mental retardation, postnatal deceleration of head growth, loss of speech and purposeful hand use, and the appearance of stereotypic hand movements. The diagnosis was made according to diagnostic criteria defined by the Rett syndrome diagnostic criteria work group (Kerr et al. 2001 ).
Molecular analyses
Genomic DNA was extracted from peripheral blood samples anticoagulated with EDTA according to a standard protocol. Coding sequences of exons 1, 2, 3, and 4 with flanking exon/intron boundaries were amplified using following primer pairs: 1Fw 5¢-tcaatc gcccctcagagca-3¢, 1Rev 5¢-cacgtcccgcccctgaccc-3¢; 2Fw 5¢-aaaaaggtcgtgcagctcaa-3¢, 2Rev 5¢-ggccaaaccaggaca tatac-3¢; 3Fw 5¢-tggcatgttctctgtgatactt-3¢, 3Rev 5¢-cctggg cacatacattttcct-3¢; 4aFw 5¢-tttgtcagagcgttgtcacc-3¢, 4aRev 5¢-ctgcacagatcggatagaagac-3¢; 4bFw 5¢-ggcaggaa gcgaaaagctgag-3¢, 4bRev 5¢-ctccctcccctcggtgtttg-3¢, 4cFw 5¢-ggagaagatgcccagaggag-3¢, 4cRev 5¢-gcactgatggcacc gaaaac-3¢. The PCR amplification of exon 1 was carried out as published elsewhere (Evans et al. 2005) , exons 2, 3, and 4 were amplified in a total volume of 25 ll including 1x Plain PP Master Mix [150 mM Tris-HCl, pH 8.8, 40 mM (NH 4 ) 2 SO 4 , 0.02% Tween 20, 5 mM MgCl 2 , 400 lM dATP, 400 lM dCTP, 400 lM dGTP, 400 lM dTTP, 100 U/ml Taq DNA polymerase; TopBio, Prague, Czech Republic] and 0.4 mM of each primer. Thermal cycling conditions included an initial denaturation at 94°C for 2 min followed by 33 cycles of denaturation at 94°C for 30 s, annealing at 63°C for 30 s, and elongation at 72°C for 45 s, followed by final extension at 72°C for 10 min.
PCR products were purified from agarose gels using a QIAquick gel extraction kit (Qiagen, Hilden, Germany). Exon 2 was analysed by conformation sensitive gel electrophoresis (CSGE) as described (Bourdon et al. 2001) . Exons 1, 3, and 4 were sequenced in both directions on automatic sequencer ABI PRISM 3100/ 3100-Avant Genetic analyzer (Applied Biosystems, Foster City, CA) using the ABI PRISM BigDye terminator v3.1 (Applied Biosystems). Whenever the identified mutation caused creation or loss of a restriction site, it was confirmed by restriction fragment length polymorphism (RFLP) analysis. To confirm del/ inv mutations, the PCR fragment with the mutation was cloned into pCR4-TOPO vector (TOPO TA Cloning Kit for Sequencing, Invitrogen, Carlsbad, CA). Plasmid DNA was amplified in Top10 chemically competent Escherichia coli cells (Invitrogen), isolated using the QIAprep Spin Miniprep Kit (Qiagen), and sequenced. We used probe mix P015 (MRC Holland, Amsterdam, The Netherlands) for MLPA in all mutation-negative patients. MLPA was performed according to manufacturer's protocol (see Supplementary material). Genotyping was performed on an ABI PRISM 3100/3100-Avant Genetic analyzer (Applied Biosystems). Aberrant results were independently re-run in the second MLPA reaction for confirmation.
Ethics
The study was carried out in accordance with the Declaration of Helsinki of the World Medical Association and was approved by the Committee of Medical Ethics at the University Hospital. Informed consent was obtained from parents of all patients.
Results
The molecular analysis revealed 31 different mutations in 68 patients (78.16%), which is consistent with estimates reported elsewhere. Of the 68 patients with mutations, 34 had a missense mutation, 18 had a nonsense mutation, 13 carried a frame-shift mutation, 1 had an in frame deletion, and 2 had large-scale deletions detected by MLPA (Table 1) . Three mutations were located in exon 3, the rest in exon 4. No sequence change was identified in exons 1 and 2. We identified six novel mutations ( Fig. 1) : two point mutations (323T>A, 904C>T), three deletions (189_190delGA, 816_832del17, 1069delAGC), and one deletion/inversion (1063_1236del174;1189_1231inv43).
We screened the parents and sisters of our patients for the mutations found in their daughters and sisters if their blood samples were available, but found none. The mutations were thus either de novo or due to germ-line mosaicism in the parents. Further sequencing analysis did not reveal any of newly described mutations in 200 normal chromosomes tested. Twelve non-pathogenic polymorphisms were identified in 14 patients, 4 of which are novel (Table 2) .
Discussion
MECP2 is an X-linked gene encoding two almost identical isoforms of MeCP2 with alternative N-termini (Mnatzakanian et al. 2004 ). The MeCP2 protein has two major functional domains: the methyl-CpG-binding domain (MBD), which binds specifically to DNA methylated at CpGs; and the transcription repression domain (TRD), which mediates transcription repression through the recruitment of other proteins (Jones et al. 1998; Nan et al. 1998) .
In this paper, we report the mutational analysis of the whole coding sequence of the MECP2 gene. Altogether, we identified a heterogeneous spectrum of mutations, including several novel MECP2 mutations and polymorphisms, in a high proportion (78.16%) of classical RTT patients. The transversion 323T>A in exon 3 leads to a substitution of a highly conserved lysine to histidine at position 108. The mutation is localized within the MBD and may affect methylationspecific binding of the protein to the DNA template. Missense mutations in the MBD most likely disrupt the integrity of the domain or interfere with MeCP2's ability to bind methylated DNA. The 904C>T transition causes the substitution of proline with serine at position 302, which lies within the TRD. This sequence change probably alters the ability of the protein to recruit co-repressor complexes and affects its function in the process of transcription repression. Mutations involving the TRD could interfere with the assembly of the transcriptional silencing complex, abolishing interactions with the Sin3A corepressor or histone deacetylase recruitment. Binding of truncated MeCP2 to methylated DNA could also provide steric hindrance to the transcription complex. MBD-containing mutant proteins without TRD might accomplish some degree of silencing, either by recruiting the silencing complex by a TRD-independent mechanism or by directly interfering with binding of transcription factors (Ballestar et al. 2000) . The 189_190delGA deletion in exon 3 causes a frame-shift, with threonine at position 63 as the first affected amino acid. The mutation introduces a premature stop codon occurring 27 codons downstream (E63fsX27). Another frameshift mutation due to a 17-bp deletion (816_832del17) creates a stop codon after 51 missense amino acids in the TRD (G273fsX52). Deletion 1069delAGC leads to the removal of one serine without alteration of the coding frame (DS357). The deleted serine is a part of the SSSASS motif (deleted S357 underlined), which is conserved between human, rat and mouse. Its function is still not clear. A combined deletion/inversion mutation 1063_1236del;1189_1231inv43 was confirmed by cloning of the affected region of the MECP2 gene into a vector and sequencing of each allele separately. The mutation alters the open reading frame, with codon 355 being the first affected, and leads to the creation of a premature stop codon 37 codons downstream (S355fsX37).
Most of the missense mutations were located in the MBD, while the nonsense mutations were more scattered, located from the end of MBD to the TRD. Deletions were located mostly in the C-terminal region. The eight most common mutations (316C>T, 397C>T, 473C>T, 502C>T, 763C>T, 808C>T, 880C>T, 916C>T), accounting for more than half of all mutations in probands with RTT, were located at CpGs, which would support the hypothesis that these motifs are mutation hot-spots, as suggested by, among others, Wan et al. (1999) .
Novel polymorphisms 1553C>T, 1789G>A, 1820G>C, and 1824G>C are localized in the 3¢UTR and do not affect the protein sequence. Unfortunately, we were not able to obtain DNA samples from the parents of these patients, hence the parental origin of the polymorphisms is unknown.
No pathogenic sequence variant was found in 19 patients, although they may have MECP2 mutations that our methods could not reveal, e.g., mutations in the promotor region or intronic variations introducing novel splice sites. There have also been suggestions that RTT is a genetically heterogeneous disorder, and that other causative genes might exist. Several recent studies identified mutations in the CDKL5 gene (OMIM 300203) encoding cyclin-dependent kinaselike 5 (formerly known as serine/threonine kinase 9; STK9) in patients with an atypical, early seizure variant of RTT (Tao et al. 2004; Weaving et al. 2004; Mari et al. 2005) . CDKL5 is a nuclear protein whose expression in the nervous system overlaps with that of MeCP2 during neural maturation and synaptogenesis. Both proteins interact in vitro and in vivo but the role of CDKL5 in the pathological mechanisms of RTT is still not clear (Mari et al. 2005) . A mutation screen of CDKL5 should be considered in mutation-negative patients with early-seizure variant RTT. Moreover, one case of a Netrin G1 mutation has been shown to be associated with a phenotype strongly overlapping that of RTT (Borg et al. 2005) , but the causal link of this mutation with RTT, if any, remains to be established.
With the discovery of mutations in the MECP2 gene, RTT became the first human disorder known to be caused by genetic defects in a component of the epigenetic silencing machinery. It is the first pervasive developmental disorder with a known genetic cause and is a prototype for the genetic, molecular, and neurobiological analysis of neurodevelopmental disorders. This study is the first report to document a mutation analysis of the MECP2 gene in RTT patients of Slavic origin.
